Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0477) | |||||
|---|---|---|---|---|---|
| DME Name | Semicarbazide-sensitive amine oxidase (AOC2), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.4.3.21 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Central neurocytoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 3.80E-09; delta-beta: -2.63E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the AOC2 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can moderatly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2A01 Meningeal tumour | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Meningioma | Moderate hypomethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 1.98E-11; delta-beta: -2.24E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the AOC2 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can moderatly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Liver cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Significant hypermethylation p-value: 9.11E-03; delta-beta: 3.39E-02 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the AOC2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can significantly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C25 Lung cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lung cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Significant hypermethylation p-value: 4.57E-03; delta-beta: 7.68E-02 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the AOC2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can significantly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C73 Ovarian cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Ovarian cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 9.48E-04; delta-beta: 3.26E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the AOC2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can significantly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 05 Endocrine/nutritional/metabolic diseases | |||||
| ICD-11: 5B81 Obesity | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Obesity | Moderate hypermethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 1.74E-05; delta-beta: 2.82E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the AOC2 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can moderatly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 12 Respiratory system diseases | |||||
| ICD-11: CB03 Idiopathic pulmonary fibrosis | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Idiopathic pulmonary fibrosis | Moderate hypomethylation | |||
| Interaction Name | DNMT-AOC2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 1.28E-03; delta-beta: -2.34E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the AOC2 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Semicarbazide-sensitive amine oxidase. As a result, the interaction between DNMT and AOC2 can moderatly affect the drug-metabolizing process of Semicarbazide-sensitive amine oxidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.